Stockreport

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

ESSA Pharma Inc.  (EPIX) 
Last essa pharma inc. earnings: 2/13 05:48 pm Check Earnings Report
US:NASDAQ Investor Relations: essapharma.com/investors
PDF Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPCPhase 2 dose expansion currentl [Read more]